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Summary
 
Proteases are now firmly established as major regulators of the “execution” phase of apoptosis.
Here, we examine the role of proteases and their relationship to ceramide, a proposed mediator
of apoptosis, in the tumor necrosis factor-
 
a
 
 (TNF-
 
a
 
)–induced pathway of cell death. Ceramide
induced activation of prICE, the protease that cleaves the death substrate poly(ADP-ribose)
polymerase. Bcl-2 inhibited ceramide-induced death, but not ceramide generation. In contrast,
Cytokine response modifier A (CrmA), a potent inhibitor of Interleukin-1
 
b
 
 converting en-
zyme and related proteases, inhibited ceramide generation and prevented TNF-
 
a
 
–induced death.
Exogenous ceramide could overcome the CrmA block to cell death, but not the Bcl-2 block.
CrmA, however, did not inhibit the activation of nuclear factor (NF)-
 
k
 
B by TNF-
 
a
 
, demon-
strating that other signaling functions of TNF-
 
a
 
 remain intact and that ceramide does not play
a role in the activation of NF-
 
k
 
B. These studies support a distinct role for proteases in the sig-
naling/activation phase of apoptosis acting upstream of ceramide formation.
 
A
 
poptosis is an essential, highly conserved, and tightly
regulated cellular process of cell death that is important
for development, host defense, and suppression of onco-
genesis (1). The intracellular mediators of apoptosis are
poorly defined. Recently, proteases belonging to the newly
described IL-1
 
b
 
 converting enzyme (ICE)
 
1
 
 family emerged
as central constituents of the apoptotic machinery. The ev-
idence implicating these proteases in the induction of apop-
tosis stems from the following observations: (
 
a
 
) homology
to the ced-3 gene product of the nematode 
 
Caenorhabditis
elegans
 
 that is required for cell death during development
(2), (
 
b
 
) induction of apoptosis when these proteases are over-
expressed in their active form (3), (
 
c
 
) inhibition of apoptosis
when these proteases are specifically inhibited (4–8), and
(
 
d
 
) identification of a number of cellular protein substrates
that are proteolytically cleaved through the specific action of
these proteases during apoptosis including poly(ADP-ribose)
polymerase (PARP) (9, 10), the 70-kD protein component
of the U1 small nuclear ribonucleoprotein (11), and others
(12). Current evidence implicates certain members of the
ICE family, particularly CPP32/Yama/apopain and ICE-
LAP3, in the execution phase of apoptosis (6, 7, 13, 14).
Also, MACH/FLICE has been recently identified as a pro-
tease in close association with the Fas receptor (15, 16).
Another important group of cell death regulators are
members of the Bcl-2 family that act as either inhibitors or
promoters of apoptosis (17–19). Bcl-2 can inhibit apoptosis
induced by a wide variety of stimuli (17, 20). However, the
mechanism of action of Bcl-2 remains unknown.
Inhibition of apoptosis is used by some DNA viruses to
attenuate host defense and increase viral progeny (21). The
cowpox virus cytokine response modifier A (CrmA) protein
that exhibits cross-class inhibition of both serine and cys-
teine proteases (22) is a potent inhibitor of apoptosis in-
duced by serum withdrawal (23), activation of the Fas or
TNF-
 
a
 
 receptors (4, 24), or withdrawal of nerve growth
factor in primary chicken neuronal cultures (25). Although
CrmA has been shown to have preferential activity against
ICE (26), it is also able to inhibit the proteolytic activity of
other members of the ICE family implicated in apoptosis,
although less potently.
Based on recent studies, the sphingolipid ceramide is
emerging as a possible regulator of apoptosis. Ceramide
 
1
 
Abbreviations used in this paper:
 
 CrmA, cytokine response modifier A;
FBS, fetal bovine serum; ICE, IL-1
 
b
 
 converting enzyme; NF, nuclear
factor; PARP, poly(ADP-ribose) polymerase.
  
482
 
CrmA Inhibits Ceramide Formation
 
can potently induce apoptosis in a number of different sys-
tems (27–30). TNF-
 
a
 
 and other inducers of apoptosis (Fas
ligation, serum withdrawal, some chemotherapeutic agents,
 
g
 
-irradiation; 29, 31–34) have been shown to elevate cellu-
lar levels of ceramide. In turn, the addition of cell-perme-
able ceramide induces apoptosis in several cell types, raising
the possibility that this may be a final pathway common to
a variety of inducers (28–30, 32). More recently, the death
signal from both Fas and TNF-
 
a
 
-receptor 1 was shown to
converge proximally on FADD, a “death domain” contain-
ing protein that belongs to a new family of signaling mole-
cules that associate with members of the TNF-
 
a
 
 receptor
family (35–38). Expression of a dominant negative mutant
of FADD inhibited ceramide accumulation, ICE-related
protease activation, and apoptosis after treatment with Fas
antibody by blocking the proximal signal. Exogenous cera-
mide was able to bypass this block and produce apoptosis
(38). Additionally, the 
 
Drososphila melanogaster
 
 protein
REAPER, which is critical for the normal development of
the 
 
Drosophila
 
 embryo, was recently found to activate apop-
tosis by the activation of an ICE-like protease associated
with ceramide generation and apoptosis (39). These effects
were blocked by the use of a specific peptide inhibitor of
ICE-like proteases. Based on these observations, it has been
suggested that ceramide may play a central role in the regu-
lation of apoptosis (40).
Here we investigate whether the antiapoptotic mole-
cules, CrmA and Bcl-2, interact with the ceramide path-
way. We show that CrmA targets this pathway upstream of
ceramide generation in response to TNF-
 
a
 
. In contrast, we
show that Bcl-2 protects from both TNF-
 
a
 
 and ceramide–
induced cell death without interfering with ceramide gen-
eration, suggesting that it functions further downstream along
the ceramide pathway. These studies identify a novel target
for inhibition of apoptosis, namely, the inhibition of cer-
amide generation, and clarify the order by which CrmA,
ceramide, and Bcl-2 interact.
 
Materials and Methods
 
Cell Lines and Cultivation.
 
The previously described cell lines
expressing CrmA or mutant CrmA and those overexpressing Bcl-2
were derived from a TNF-
 
a
 
–sensitive MCF-7 parental line (4, 6,
41) (gift of Muneesh Tewari and Dr. Vishva Dixit, University of
Michigan, Ann Arbor). Cells were grown in RPMI 1640 medium
supplemented with 10% fetal bovine serum (FBS) and 0.2% so-
dium bicarbonate. 500 
 
m
 
g/ml G418 was added to the CrmA cell
line and its vector while 150 
 
m
 
g/ml hygromycin was added to the
Bcl-2 cell line and its vector. Experiments were done in the ab-
sence of G418 or hygromycin. Cell viability was determined by
the ability to exclude trypan blue.
 
Ceramide Measurement.
 
Cells were seeded at 2 
 
3
 
 10
 
5
 
 cells/ml
in a 10 ml volume, rested overnight, and then treated with 1.2
nM TNF-
 
a
 
. Lipids were collected according to the method of
Bligh and Dyer (42). In brief, cells were pelleted, washed once
with PBS, and then extracted with 3 ml chloroform/methanol (1:2,
vol/vol) in 13 
 
3
 
 100 mm screw-top glass tubes. The monophase
was mixed, 0.7 ml water was added, and the samples were rested
for 10 min. The organic and aqueous phases were subsequently
separated by addition of 1 ml chloroform and 1 ml water fol-
lowed by vigorous shaking and centrifugation at 1,000 rpm. The
organic phase was carefully removed and transferred to a new
tube, and the samples were dried under N
 
2
 
. Lipids were then re-
suspended in 1 ml of chloroform. Ceramide levels were measured
using a modified diacylglycerol kinase assay (43, 44) using exter-
nal standards. In brief, 80% of the lipid sample was dried under
N
 
2
 
. The dried lipid was solubilized in 20 
 
m
 
l of an octyl-
 
b
 
-
 
d
 
-gluco-
side/dioleoyl phophatidylglycerol micellar solution (7.5% octyl-
 
b
 
-
 
d
 
-glucoside, 25 mM dioleoyl phosphatidylglycerol) by 2 cycles
of sonication in a bath sonicator for 60 s followed by resting at room
temperature for 15–20 min. The reaction buffer was prepared as a
2 
 
3
 
 solution containing 100 mM imidazole HCL, pH 6.6, 100
mM LiCl, 25 mM MgCl
 
2
 
, 2 mM EGTA. To the lipid micelles, 50
 
m
 
l of the 2 
 
3
 
 reaction buffer were added, 0.2 
 
m
 
l of 1 M dithiothrei-
tol, 5 
 
m
 
g of diglycerol kinase membranes, and dilution buffer (10
mM imidazole, pH 6.6, 1 mM diethylenetriaminepentaacetic acid,
pH 7) to a final volume of 90 
 
m
 
l. The reaction was started by adding
10 
 
m
 
l 2.5 mM [
 
g
 
-
 
32
 
P]ATP solution (specific activity of 75,000–
200,000 cpm/nmol). The reaction was allowed to proceed at
25
 
8
 
C for 30 min. Lipids were extracted as described above and a
1.5-ml aliquot of the organic phase was dried under N
 
2
 
. Lipids
were then resuspended in a volume of 100 
 
m
 
l methanol/chloro-
form (1:20, vol/vol) and 20 
 
m
 
l was spotted on a 20-cm silica gel
thin layer chromatography plate. Plates were developed with chlo-
roform/acetone/methanol/acetic acid/H
 
2
 
O (50:20:15:10:5), air
dried, and then subjected to autoradiography. The radioactive spots
corresponding to phosphatidic acid and ceramide phosphate, and
the phosphorylated products of diacylglycerol, and ceramide, re-
spectively, were scraped into a scintillation vial containing 4 ml
scintillation fluid and counted on a scintillation counter. Linear
curves of phosphorylation were produced over a concentration
range of 0–640 pM of external standards (dioleoyl glycerol and CIII
ceramide; Sigma Chemical Co., St. Louis, MO). Diacyglycerol and
ceramide levels were always normalized to lipid phosphate which
was measured according to the method of Rouser et al. (45). In
brief, 20% of the lipid sample was dried down under N
 
2
 
 and oxi-
dized with 150 
 
m
 
l of 70% perchloric acid on a heating block at
160
 
8
 
C for 45 min. The tubes were allowed to cool, and then 830 
 
m
 
l
of H
 
2
 
0 was added, followed by 170 
 
m
 
l of 2.5% ammonium mo-
lybdate, and 170 
 
m
 
l of 10% ascorbic acid with vortexing after
each addition. The tubes were then incubated at 50
 
8
 
C for 15
min, allowed to cool, and absorbance read at 820 nm and com-
pared to standard.
 
Measurement of Ceramide Uptake.
 
Cells were seeded at 2.5 
 
3
 
10
 
5
 
/well of a 6-well plate in a 2-ml volume of RPMI with 2%
FBS and treated with 
 
14
 
C
 
6
 
ceramide at 20 
 
m
 
M. Cells were har-
vested by scraping at the indicated time points, washed twice
with PBS, and the radioactivity retained in the pellet was counted
in a scintillation counter.
 
Preparation of Cell Lysates.
 
For experiments analyzing PARP
proteolysis, cells were seeded and treated as described for the cer-
amide measurement experiments. At the indicated time points,
cells were harvested by scraping in media followed by centrifuga-
tion at 4
 
8
 
C and washed once with ice-cold PBS. The cell pellet
was then resuspended in 50 
 
m
 
l PBS and lysed with sample buffer
(30 mM Tris-HCL [pH 6.8], 10% glycerol, 6% 
 
b
 
-mercaptoetha-
nol, 4% SDS) and boiled for 10 min. Protein concentrations were
determined using the Bio-Rad assay.
 
Western Blotting.
 
Equal amounts of protein, usually 100 
 
m
 
g,
were resolved by SDS-PAGE and transferred to a nitrocellulose
membrane. PARP and its cleaved fragment were detected using a
rabbit polyclonal antiserum at a dilution of 1:2,000, and a goat 
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anti–rabbit secondary antibody at a dilution of 1:5,000. The signal
was visualized by enhanced chemiluminescence (Amersham Intl.,
Buckinghamshire, UK).
 
Nuclear Factor-
 
k
 
B Assay.
 
Nuclear extracts were prepared as
described previously (46, 47). In brief, 2 
 
3
 
 10
 
6
 
 cells were washed
once in PBS. The cell pellet was rapidly frozen in dry ice and
isopropanol, and then thawed by adding 100 
 
m
 
l of ice-cold buffer
A (10 mM Hepes, pH 7.9, 10 mM KCl, 1.5 mM MgCl
 
2
 
, 1 mM
dithiothreitol) resulting in 100% cell lysis. The nuclei were pel-
leted by microcentrifugation at 3,500 rpm for 10 min at 4
 
8
 
C. The
supernatant was discarded and the nuclei suspended in 15 
 
m
 
l of
buffer C (20 mM Hepes, pH 7.9, 0.4 M NaCl, 1.5 mM MgCl
 
2
 
,
25% vol/vol glycerol, 0.2 mM EDTA, 1 mM dithiothreitol, 0.5
mM phenylmethylsulfonyl fluoride). The suspension was mixed
gently for 20 min at 4
 
8
 
C, and then microcentrifuged at 14,000
rpm for 20 min at 4
 
8
 
C. The supernatant was diluted with 50–70 
 
m
 
l
of buffer D (20 mM Hepes, pH 7.9, 50 mM KCl, 20% vol/vol
glycerol, 0.2 mM EDTA, 1 mM dithiothreitol, 0.5 mM phenyl-
methylsulfonyl  fluoride) and aliquots stored at 
 
2
 
80
 
8
 
C. Protein
concentrations were determined using the Bio-Rad assay. Electro-
phoretic mobility-shift assay reactions were performed in 20 
 
m
 
l
volume, using 8–10 
 
m
 
g of nuclear extract in the presence of 1 
 
m
 
g
of poly(d[I-C]) 1 
 
m
 
g of pd(N)
 
6
 
, and 10 
 
mg of BSA. Incubations
were in the presence of HDKE buffer with the following final
concentrations: 20 mM Hepes, pH 7.9, 50 mM KCl, 1 mM
EDTA, and 5 mM dithiothreitol. Reactions were started by the
addition of 10,000–50,000 cpm radiolabeled nuclear factor (NF)-
kB oligonucleotide probe (Promega Corp., Madison, WI). After
incubation for 10 min, the reactions were terminated by adding 6
ml of 15% ficoll solution containing indicator dyes. Equal
amounts of the reactions were loaded on 5% nondenaturing poly-
acrylamide gels in 1 3 Tris/Borate/EDTA and run at 200 volts.
Specificity of the NF-kB bands was determined by competition
with excess unlabeled probe and lack of competition with 100-
fold excess of a probe containing a one basepair mutation in the
NF-kB binding sequence.
Results
Ceramide Accumulation Is Delayed, but Precedes Early Apop-
totic Signs. We treated MCF-7 breast carcinoma cells with
TNF-a and measured ceramide levels and cell death con-
comitantly at several time points (Fig. 1 A). Ceramide lev-
els did not change appreciably in the first 5 h (data not
shown) but were significantly increased between 7 and 9 h
and continued to increase with time, up to 400% by 20 h.
This accumulation was not dependent on new protein syn-
thesis since the addition of cycloheximide to the cells be-
fore treatment with TNF-a enhanced the accumulation of
Figure 1. (A) Effects of TNF-a
on cell death and ceramide levels
in MCF-7 cells. MCF-7 breast
carcinoma cells were treated
with TNF-a at 1.2 nM. At the
indicated time points, adherent
and floating cells were harvested
and the number of dead cells was
determined by their inability to
exclude trypan blue (open circles).
Concomitantly, lipids were col-
lected and ceramide levels were
measured (filled circles) and com-
pared to time-matched controls.
Levels of ceramide in control
cells ranged between 4–6 pmole/
nmole of lipid phosphate. Re-
sults are averages of three experi-
ments. Standard deviation for all
points is indicated. (B) Effect of cycloheximide on ceramide accumulation after TNF-a. MCF-7 cells were treated with TNF-a at 1.2 nM as in A in the
presence of increasing concentrations of cycloheximide as indicated. Cells were harvested at 18 h after TNF-a treatment, and ceramide levels were mea-
sured in the lipid extracts.
Figure 2. Kinetics of PARP cleavage after TNF-a treatment. MCF-7
cells were seeded at 2 3 106 cells/10-cm plate, rested overnight, and then
treated as in Fig. 1. At the indicated time points, cells were harvested by
scraping in media to insure inclusion of the floating cells at later time
points. Cell lysis and Western blotting were performed as described in
Materials and Methods. Densitometric analysis of the two resulting bands
was performed. The cleaved PARP fragment is represented as a percent
of the total of both fragments. A representative experiment is shown (out
of three).484 CrmA Inhibits Ceramide Formation
ceramide (Fig. 1 B). Although these are delayed and persis-
tent changes in ceramide, it is becoming increasingly appar-
ent that this is the pattern most closely related to the apop-
totic responses. Although this raises the concern that ceramide
accumulation is a consequence of death, studies with Bcl-2
(see below) negate this possibility. Cell death, as measured
by the inability to exclude trypan blue, was not seen until
20 h, occurring several hours after the increase in ceramide
levels, indicating that ceramide accumulation occurs long
before loss of membrane integrity. To verify that cell death
was occurring through induction of apoptosis, we assayed
for cleavage of the 116-kD PARP polypeptide to a specific
85-kD apoptotic fragment (9, 10). This proteolytic cleav-
age has been shown to occur in apoptosis and to be medi-
ated by Yama/CPP32/apopain or related proteases. As
shown previously (6), treatment of MCF-7 cells with
TNF-a resulted in specific cleavage of PARP to the 85-kD
fragment (Fig. 2). Significant PARP cleavage did not occur
until 12 h after treatment with TNF-a and was maximal by
25 h. These results indicate that ceramide accumulation
precedes one of the early signs of apoptosis, i.e., PARP
cleavage, by at least 3–4 h. Moreover, loss of cell mem-
brane integrity, as determined by trypan blue uptake, is un-
likely to contribute to ceramide accumulation since it oc-
curs several hours after the dramatic increase in endogenous
ceramide levels.
CrmA Prevents Ceramide Accumulation The ability of CrmA
to inhibit, with variable efficiency, the ICE family of cys-
teine proteases (6, 7, 22, 26) was used to examine the re-
lationship of these proteases to ceramide along the death
pathway. MCF-7 cells stably expressing CrmA were treated
with 2 nM TNF-a or increasing concentrations of C6-cer-
amide, a cell-permeable ceramide analogue, and compared
with control (vector) cells. As shown previously (4), CrmA
offered almost complete protection from TNF-a–induced
cytotoxicity (Fig. 3 A). However, CrmA offered no pro-
tection from the cytotoxic effects of ceramide so that cells
died equally in the presence or absence of CrmA (Fig. 3 A).
Comparison of another pair of vector and CrmA-expressing
MCF-7 clones described previously (4) yielded similar re-
sults (data not shown). Therefore, CrmA appeared not to
interfere with the downstream effects of ceramide.
Figure 3. Effects of CrmA on the TNF-a–activated ceramide pathway.
(A) CrmA protects from TNF-a–induced, but not ceramide-induced, cell
death. TNF-a–sensitive MCF-7 cells transfected with either pcDNA3 vec-
tor (open bars) or pcDNA3/crmA (filled bars) were seeded in 24-well plates
at 5 3 104 cells/well in 2% FBS, rested overnight, and then treated with
the indicated concentrations of C6-ceramide or 2 nM TNF-a. Cell death,
determined by the inability to exclude trypan blue, was evaluated at 48 h.
(B) CrmA inhibits ceramide generation after TNF-a stimulation. The
CrmA-expressing MCF-7 cells (filled circles) and their vector control cells
(open circles) were treated with TNF-a as in Fig. 1. Ceramide levels were
measured at the indicated time points as in Fig. 1. Results are the average
of three experiments with the standard deviation indicated. (C) Antipro-
teolytic activity of CrmA is important in inhibiting ceramide accumula-
tion. Cells expressing CrmA, point-mutant CrmA, or wild-type MCF-7
cells pretreated 1 h with 50 mm Ac-YVAD-CHO (Bachem, King of
Prussia, PA) were treated, along with their respective controls, with 1.2
nM TNF-a for 18 h. Ceramide was then measured as in Fig. 1. Percent
inhibition was calculated by comparison with the results from TNF-a–
treated controls. The average of three experiments is shown.485 Dbaibo et al.
Since endogenous ceramide elevation may drive the
cell to die, we next examined whether CrmA interferes
with ceramide generation. We measured endogenous cer-
amide levels in response to TNF-a in control and in CrmA-
expressing MCF-7 cells. Ceramide levels increased dramat-
ically in vector cells at 18 and 24 h (Fig. 3 B). However,
CrmA-expressing cells treated similarly with TNF-a showed
no increase in ceramide levels. To determine whether the
inhibition of ceramide accumulation was dependent on the
ability of CrmA to inhibit proteases, we used two ap-
proaches. First, we used a point-mutant of CrmA that has
no antiproteolytic activity due to the substitution of Arg for
Thr at amino acid 291 in the reactive site loop (6). In
MCF-7 cells expressing this mutant, there was no signifi-
cant inhibition of ceramide accumulation (Fig. 3 C) and no
protection from TNF-a–induced apoptosis (6). Second,
we used the synthetic peptide Ac-YVAD-CHO that, like
CrmA, is a potent competitive inhibitor of ICE (7). Pre-
treatment of cells with this peptide, resulted in significant
inhibition of ceramide accumulation after TNF-a treat-
ment (Fig. 3 C). In contrast, other protease inhibitors not
known to inhibit the ICE family of proteases, including
N-tosyl-l-phenylalanine chloromethyl ketone and leupep-
tin,  were unable to inhibit ceramide accumulation after
TNF-a treatment (data not shown). Therefore, CrmA in-
hibits TNF-a–induced apoptosis by acting at a point up-
stream of the generation of ceramide, and this inhibition is
dependent on its antiproteolytic activity.
Bcl-2 Inhibition of Apoptosis Is Downstream of Ceramide Genera-
tion. As ceramide generation occurred in cells destined to
die due to treatment with TNF-a and not in the protected,
CrmA-expressing cells, it became important to verify that
this increase in ceramide levels, as well as the suppression of
this increase by CrmA, were specific events correlating
with cell death or survival, respectively. We used Bcl-2,
another antiapoptotic molecule that has recently been
shown to protect from ceramide-induced apoptosis (48,
49). MCF-7 cells expressing Bcl-2 or vector controls were
treated with TNF-a or increasing concentrations of C6-cer-
amide. Control cells died in response to both treatments,
but Bcl-2–expressing cells displayed resistance to TNF-
a–induced cell death as seen in cells expressing CrmA (Fig.
4 A). However, unlike CrmA-expressing cells, Bcl-2–express-
ing cells were resistant to ceramide-induced cell death. Addi-
tionally, generation of endogenous ceramide was nearly equal
in both vector and Bcl-2 cells in response to TNF-a, indi-
cating that Bcl-2 does not interfere with ceramide genera-
tion (Fig. 4 B). Therefore, Bcl-2 functions at a point
downstream of ceramide to inhibit apoptosis. More impor-
tantly, this delayed accumulation of ceramide is not a con-
sequence of cell death since it is still observed in the viable
Bcl-2–expressing cells. Thus, these data demonstrate that the
elevation in ceramide is proximal to the biochemical and
morphological changes of cell death.
Ceramide-Induced PARP Cleavage Is Inhibited by Bcl-2, but
Not CrmA. To determine the relationship between TNF-a,
ceramide, and subsequent PARP cleavage and apoptosis, it
became imperative to study the effects and kinetics of cer-
amide on PARP cleavage. Consistent with results in Molt
4 cells (50), treatment of MCF-7 cells with ceramide re-
sulted in cleavage of PARP (Fig. 5 A), and PARP cleavage
after 4 h of ceramide treatment was equivalent to that caused
by 12–16 h of TNF-a treatment (compare with Fig. 2).
By using 14C-labeled ceramide and evaluating the kinetics
of its uptake by MCF-7 cells at several time points, we
found that ceramide was taken up slowly by these cells
with maximal uptake reached at only 4 h (Fig. 5 B). There-
fore, the delay in PARP cleavage after ceramide treatment
can be attributed to the delay in uptake of exogenous cer-
amide. Hence, these experiments support the hypothesis that
ceramide accumulation following TNF-a treatment may
represent a trigger for PARP cleavage and apoptosis.
Next, it became important to determine the effect of
CrmA or Bcl-2 expression on ceramide-induced PARP
cleavage in MCF-7 cells. Although both Bcl-2 and CrmA in-
hibited TNF-a–induced PARP cleavage, only Bcl-2 expres-
sion provided protection from ceramide-induced cleavage.
PARP was cleaved after exogenous ceramide treatment de-
Figure 4. Effects of Bcl-2 over-
expression on the TNF-a–acti-
vated ceramide pathway. (A) Bcl-2
prevents both TNF-a– and cer-
amide–induced cell death. TNF-a–
and Fas–sensitive MCF-7 cells
overexpressing pEBS7 (open bars)
or pEBS7/Bcl-2 (filled bars) were
treated as in Fig. 3 A and evalu-
ated for cell death by trypan blue
at 48 h. (B) Bcl-2 does not pre-
vent the TNF-a–induced eleva-
tion in ceramide levels. The Bcl-
2–overexpressing MCF-7 cells
(filled diamonds) and control vec-
tor cells (open circles) were treated
as in Fig. 3 B, and ceramide lev-
els were measured at the indi-
cated time points.486 CrmA Inhibits Ceramide Formation
spite high levels of expression of CrmA, indicating that
ceramide bypasses the CrmA target and activates a down-
stream protease capable of cleaving PARP (i.e., prICE)
(Fig. 5 C). Densitometric quantitation of PARP cleavage
showed 17.7 and 20.4% cleavage in the ceramide– or
TNF-a–treated vector cells, respectively, whereas CrmA-
expressing cells treated with ceramide or TNF-a had 16.6
and 0% cleavage, respectively. Therefore, in MCF-7 cells,
CrmA expression does not significantly interfere with acti-
vation of PARP cleavage by ceramide.
CrmA Does Not Protect from a Ceramide-Independent Path-
way of Apoptosis. To further dissociate the site of action of
CrmA from that of Bcl-2, we employed the alkylating agent
mitomycin C. Mitomycin C did not cause any significant
change in endogenous ceramide levels (data not shown).
We next compared the effects of TNF-a, C6-ceramide, and
mitomycin C on the survival of CrmA– or Bcl-2–express-
ing MCF-7 cells. Whereas the CrmA-expressing cells were
protected from TNF-a–induced apoptosis, they were equally
susceptible to mitomycin C (Fig. 6 A) as were vector cells.
However, cells expressing Bcl-2 were protected from the
cytotoxic effects of mitomycin C as well as TNF-a and cer-
amide. Biochemically, expression of CrmA prevented PARP
cleavage after activation of the ceramide-dependent TNF-a
pathway (Fig. 6 B). However, PARP cleavage was almost
complete, despite expression of CrmA, after treatment with
mitomycin C that activates a ceramide-independent apop-
totic pathway. In contrast, Bcl-2 overexpression prevented
PARP cleavage induced by both the TNF-a (ceramide-
dependent) and mitomycin C (ceramide-independent)
pathways. These results provide additional evidence that
CrmA functions distinctly from Bcl-2. Specifically, CrmA
appears to inhibit an event proximal to ceramide accumula-
tion in ceramide-dependent pathways whereas Bcl-2 works
by inhibiting a more distal target that is common to both
apoptotic pathways.
CrmA-Induced Block of Ceramide Accumulation Does Not
Affect NF-kB Activation. Activation of the transcription
factor NF-kB is one of the major functions of TNF-a. For
activation to occur, NF-kB has to dissociate from its cyto-
plasmic inhibitory protein I-kB so that it can translocate to
the nucleus (51). This is accomplished through site-specific
serine phosphorylation followed by proteolytic degradation
of I-kB (52, 53). The mediators of this activation have not
been clarified, although the “death domain”-containing
protein TRADD, but not FADD, has been shown to be
important for its activation (35, 36). Recently, ceramide
generated through the action of an acidic sphingomyelinase
was implicated in the activation of NF-kB (54). The anti-
proteolytic activity of CrmA, as well as its ability to inhibit
ceramide accumulation after TNF-a treatment led us to
examine the effect of CrmA expression on NF-kB activa-
tion. We used electrophoretic mobility shift assays which
rely on the ability of activated NF-kB to bind to its specific
DNA sequence resulting in retardation of the protein–
DNA complex on nondenaturing polyacrylamide gels. Treat-
ment of MCF-7 cells expressing CrmA, Bcl-2, or their
corresponding vector with 2 nM TNF-a resulted in equal
activation of NF-kB (Fig. 7, A and B). Therefore, CrmA
does not interfere with the signaling pathway leading to ac-
tivation of NF-kB, despite its demonstrated ability to com-
pletely inhibit ceramide accumulation. This suggests that a
Figure 5. (A) Kinetics of PARP cleavage after ceramide treatment.
MCF-7 cells were seeded and treated with ceramide, and then harvested
at the indicated time points. PARP cleavage was assayed as in Fig. 2. In-
tact PARP (116 kD) and its cleaved product (85 kD) are indicated. (B)
Kinetics of exogenous ceramide uptake. MCF-7 cells were seeded and
treated with 14C6-ceramide (specific activity of 1.5 3 1013 cpm/mole) at a
similar concentration. At the indicated time points, cells were harvested,
washed twice with PBS, and the radioactivity retained in the pellet was
counted and presented as a percent of total radioactivity delivered. (C) Ef-
fects of CrmA and Bcl-2 on ceramide-induced PARP cleavage. Vector,
CrmA-expressing, or Bcl-2–overexpressing cells were seeded at 2.5 3 105
cells/well of a 6-well plate. The cells were rested overnight then treated
with vehicle (V) or ceramide (C) for 8 h or TNF-a (T) for 16 h. The final
concentration of ceramide was 0.32 pmole/cell, and 1.2 nM for TNF-a.
Cells from a total of six wells for each treatment were then harvested,
combined, and PARP cleavage was assayed as in Fig. 2.487 Dbaibo et al.
physiologic role for ceramide in NF-kB activation is un-
likely.
Discussion
The results from this study show that ceramide accumu-
lation observed after treatment of MCF-7 cells with TNF-a
is completely inhibited by CrmA (Fig. 3 B). Exogenous cer-
amide can bypass this block and produce apoptosis by acti-
vation of downstream proteases (Fig. 3 A and 5 A). Similar
results were obtained with BJAB cells after ligation of the
Fas receptor (data not shown). These data suggest that
CrmA targets a protease acting upstream of ceramide gen-
eration. Since CrmA did not inhibit activation of prICE by
ceramide or mitomycin C, these results raise the possibility
that CrmA may target proteases that act upstream of the
PARP protease.
The antiapoptotic activity of CrmA has been thought to
be due to its ability to inhibit members of the ICE family of
cysteine proteases that are homologues of the C. elegans cell
death protease CED-3 (2, 4, 25). However, the potency by
which CrmA inhibits the various members of this family
varies significantly. Whereas picomolar concentrations of
CrmA can potently inhibit ICE, concentrations that are
over 1,000-fold higher are required to achieve comparable
inhibition of Yama/CPP32/apopain, a putative PARP cleav-
ing protease (7). Similarly, CrmA is a poor inhibitor of
ICH-1 (23) and CED-3 (3, 55), indicating that it preferen-
tially targets only a subset of ICE family members. This
may explain why CrmA is not a universal inhibitor of apop-
tosis. Based on our findings, the more physiologically rele-
vant target of CrmA appears to be a protease that is acti-
vated by TNF-a and is involved in the activation phase,
rather than the execution phase, of apoptosis. The recently
described Fas– and TNF-a receptor–associated ICE pro-
tease FLICE/MACH, is a likely candidate since it was
demonstrated that apoptosis induced by its overexpression
can be inhibited by CrmA (16). Other apoptotic stimuli
such as mitomycin or sodium azide (data not shown) that
use a ceramide-independent pathway to activate the death
proteases are not inhibited by CrmA (Fig. 8).
Our findings define a novel site of CrmA-induced pro-
tection from apoptosis that is clearly distinct from that of
Bcl-2. Whereas CrmA interferes with ceramide accumula-
tion, Bcl-2 does not modulate this event and appears to
work downstream by inhibiting the execution machinery
of apoptosis (Fig. 8). This is additionally supported by the
ability of both CrmA and Bcl-2 to protect from cell death
when induced with TNF-a while only Bcl-2 is capable of
protecting cells treated with C6-ceramide or mitomycin C.
Figure 6. Differential protection from cell death by CrmA and Bcl-2.
(A) Vector, CrmA-expressing, and Bcl-2–overexpressing MCF-7 cells were
treated as in Fig. 3 A with C6-ceramide (10 mM), TNF-a (2 nM), or mi-
tomycin C (2.5 mg/ml). Cell death was evaluated at 48 h as in Fig. 2 A.
Results are the average of three experiments. (B) Vector, CrmA-express-
ing, and Bcl-2–overexpressing MCF-7 cells were seeded as in Fig. 2 and
treated with PBS vehicle (lane 1), 1.2 nM TNF-a (lane 2), or 10 mg/ml
mitomycin C (lane 3). Cells were harvested after 20 h of treatment and
PARP cleavage was assayed as in Fig. 2. The bands representing intact or
cleaved (apoptotic) PARP are shown. One out of three different experi-
ments is shown.
Figure 7. Activation of NF-kB is not inhibited by CrmA (A) or Bcl-2
(B). Electrophoretic mobility shift assay (EMSA) for the transcription fac-
tor NF-kB in MCF-7 cells expressing CrmA, Bcl-2, or vector is shown.
Cells were seeded at 2 3 106 cells/10-cm dish in RPMI media containing
10% FBS and rested overnight. Treatment with 2 nM TNF-a proceeded
for 30 min after which the cells were trypsinized, nuclear extracts prepared,
and EMSA performed using 10 mg of nuclear protein and a 32P-labeled
NF-kB oligonucleotide probe as described in Materials and Methods. Bands
representing the specific NF-kB-DNA complex, a nonspecific band (n.s.),
and the free probe are indicated.488 CrmA Inhibits Ceramide Formation
These findings implicate Bcl-2 as a more generalized inhib-
itor of apoptosis acting on a target common to different apop-
totic pathways whereas CrmA may specifically inhibit path-
ways that lead to a sustained ceramide signal such as that
stimulated by TNF-a or Fas.
These studies also define distinct pathways that lead to
NF-kB activation and apoptosis. The activation of the cer-
amide pathway has been implicated by some groups to be a
necessary step for activation of NF-kB (54, 56, 57). Others
have been unable to reproduce these results (47, 58–61).
The ability of CrmA to inhibit the generation of ceramide
provided a new tool to help resolve these contradictions.
Our finding that CrmA does not inhibit NF-kB activation
by TNF-a despite a complete shutdown of ceramide gen-
eration makes a role for ceramide in NF-kB activation highly
questionable. Rather, ceramide accumulation appears to be
more intimately related to apoptosis and growth suppres-
sion. These results are consistent with published studies
showing that CrmA does not interfere with NF-kB acti-
vation stimulated by TRADD overexpression, but blocks
TRADD-driven apoptosis (36), and that the dominant nega-
tive FADD mutant can potently suppress FADD-depen-
dent apoptosis without interfering with NF-kB activation
(38). Additionally, in cells undergoing Fas-induced apopto-
sis which is accompanied by massive accumulation of cer-
amide, NF-kB activation is strikingly absent (Gamard, C.,
G. Dbaibo, L. Obeid, and Y. Hannun, manuscript submit-
ted). These studies clearly support the previous findings that
ceramide is neither necessary nor sufficient for NF-kB acti-
vation.
Taken together, these findings are consistent with an im-
portant role for ceramide in TNF-a–induced apoptosis.
The sustained elevations in endogenous ceramide levels
observed over several hours that are inhibited by CrmA are
more closely related to apoptosis than the transient, but
more modest, increases in ceramide observed within min-
utes in other cell lines and implicated in mediating early
signaling events (27). Indeed, these sustained levels of cer-
amide are more compatible with cellular levels achieved
with 1–20 mM of exogenous ceramide. Accumulation of
ceramide with delayed kinetics has been implicated as a
stress response that drives the cell to either undergo apopto-
sis (29, 34) or cell cycle arrest (29, 62). Indeed, these delayed
kinetics of ceramide accumulation are more commensurate
with the observed delay in the onset of apoptotic morphol-
ogy and subsequent cell death after TNF-a. Our findings
that this accumulation occurs before PARP cleavage and
the ability of Bcl-2 to prevent ceramide-induced death sup-
port this emerging role for ceramide. The results obtained
using MCF-7 cells suggest that, in the apoptotic response of
these cells, ceramide functions much more as a downstream
sensor and integrator rather than as an upstream acute sig-
naling switch.
In conclusion, ceramide accumulation is emerging as an
important component in a TNF-a–induceable pathway of
apoptosis. This pathway can be inhibited by CrmA that
blocks ceramide generation or Bcl-2 that interferes with
the function of effector molecules downstream of ceramide
(Fig. 8). Although both Bcl-2 and CrmA appear to inhibit
activation of proteases, these results show that they inter-
fere with the death pathway at two different points. These
results will need to be evaluated in other cell lines and fur-
ther exploration of this pathway will be essential for the
understanding of this complex aspect of cell regulation and
may identify more specific targets for inhibition of apoptosis.
Figure 8. Schematic presentation of the proposed sites of inhibition of
the ceramide pathway by CrmA and Bcl-2. Activation of sphingomyelin-
ases requires several stages of proteolytic processing (63). The inhibition
of ceramide accumulation by CrmA is hypothesized to be due to its abil-
ity to inhibit cysteine or serine proteases probably involved in the pro-
cessing of sphingomyelinase(s). Bcl-2 functions further downstream by in-
hibiting effector molecules involved in the execution of the death order
without interfering with the generation of ceramide. The specific target
of Bcl-2 is not yet known. The diagram illustrates the possibility that ei-
ther proteases or regulatory molecules are targeted by Bcl-2.
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